Abstract:
Disclosed is a process for preparing 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide hydrochloride, an intermediate useful in the preparation of the HCV protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide.
Abstract:
Fluorinated alkene compounds useful for and methods of controlling nematodes, insects, and acarids that prey on agricultural crops. Polar compounds, for example, 3,4,4-trifluoro-3-butene-1-amine or 3,4,4-trifluoro-3-butenoic acid, are particularly useful for systemic control of pests. Novel method and intermediates for the preparation of 3,4,4-trifluoro-3-butene-1-amine are also provided.
Abstract:
Methods and compositions are provided for the direct catalytic asymmetric aldol reaction of aldehydes with donor molecules selected from ketones and nitroalkyl compounds. The reactions employ as catalyst a Group 2A or Group 2B metal complex of a ligand of formula (I), as defined further herein.
Abstract:
The present invention relates to compounds of the general formula: NO2-A-B wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 carbon atoms and B is (CH2)n(COOH)m in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or of general formula (I), wherein A' is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B' is (CH2)j(COOH)k in which j is an integer from 1 to 3 and k is 0 or 1; and the derivatives thereof in which the hydrocarbon chain includes one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy. These compounds have biological activity, e.g. as anti-infective or anti-inflammatory agents.
Abstract:
Die vorliegende Erfindung beschreibt eine optimierte Synthese von Pregabalin sowie weiteren 4-Aminobutansäuren unter Einsatz eines verbesserten Herstellverfahrens von konjugierten Nitroalkenen. Dies wird erreicht durch direkt aufeinanderfolgende Nitro-Aldol-Reaktion eines aliphatischen Aldehyds mit einem Nitroalkan in Gegenwart eines geeigneten Diamins und Eliminierung des konjugierten Nitroalkens durch Zugabe einer Säure, anschließender katalysierter asymmetrischer 1,4-Michael-Addition eines geeigneten Nucleophils, einer daran anschließenden Retro-Claisen-Reaktion bzw. einer Verseifung und Decarboxylierung mit abschließender Reduktion zur 4-Aminobutansäure.
Abstract:
Embodiments in accordance with the present invention provide for non-self imageable norbornene-type polymers useful for immersion lithographic processes, methods of making such polymers, compositions employing such polymers and immersion lithographic processes that make use of such compositions. More specifically the embodiments of the present invention are related to norbornene-type polymers useful for forming top-coat layers for overlying photoresist layers in immersion lithographic process and the process thereof.
Abstract:
Disclosed are porous polymer/carrier solid phase reactants which consist of a polymer that consists of fine particles and is situated in the pore space of porous carrier materials. Reactive groups are bound to the polymer. Said groups act as reactants in organic-chemical syntheses. Said solid phase reactants can be produced as bulk material or tubes, plates or rods, can be built in pressure sealed housings and can be used in flow-through apparatuses or microtitration fields for the synthesis of organic products. Potential active agents can be produced at high speed by using the inventive porous polymer/carrier solid phase reactants that can be flown through convectively, whereby production requires only little isolation and cleaning.
Abstract:
The present invention relates to pharmaceutical compositions comprising, as an anti-cancer agent: (a) one or more compounds having the formula NO2-A-B, wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 double bonds, and B is (CH2)m(COOH)n in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; (b) one or more compounds selected from polyunsaturated fatty acids (PUFA's) having a 16 to 26 carbon atom chain and 3 to 6 double bonds, and wherein the PUFA is covalently coupled at the carboxylic acid group to an amino acid selected from glycine and aspartic acid; (c) one or more compounds selected from unsaturated fatty acids having an 18 to 25 carbon atom chain and 1 to 6 double bonds and wherein the fatty acid has one or two beta -oxa, gamma -oxa, beta -thia, gamma -thia substitutions; or (d) one or more compounds having formula (I) wherein A' is a saturated or unsaturated hydrocarbon chain of 9-26 carbon atoms, X is oxygen or is absent and B' is (CH2)j(COOH)k in which j is an integer from 1 to 3 and k is 0 or 1; or a derivative thereof in which the hydrocarbon chain has one or more than one substitution selected from the group consisting of hydroxy, hydroperoxy, epoxy and peroxy; and a pharmaceutically acceptable carrier or diluent.
Abstract:
A novel process of preparation of racemic pregabalin from comprising an intermediate of structure III comprising reductive ring opening to form a structure IV followed few alternative routes that yield racemic pregabalin that is resolved to yield (S) + pregabalin by using chemical or enzymatic methods. A new chemical entity of structure IIIc is also disclosed as a novel intermediate. A part of the novel process also comprises a new process of producing a compound of structure VII comprising acylation of compound of structure V followed by elimination and improving a process of producing a compound of structure VII comprising reacting isovaleraldehyde with nitromethane through the compounds 4-methyl-1-nitropentan- 2-ol, 3-methyl-1-(nitromethyl)butylacetate, and 3-methyl-1-(nitromethyl)butyl acetate under suitable conditions to 4-methyl-1-nitropet-1-ene. Enzymatic processes of resolution of racemic pregabalin esters into (S) pregabalin and (R) pregabalin are also disclosed.